Biohm Technologies has partnered with ADM to launch a new data-driven, targeted microbiome formulation for women’s health. The formulation, Vivifem, is a combination of pre-, pro-, and postbiotics designed specifically for women’s healthy aging goals.
 
ADM’s product development experts employed Biohm Technologies’ Symbiont platform, which is the company’s systematic approach to ingredient discovery, selection, and formulation with the proprietary microbiome dataset at its core. The resulting product is called Vivifem, which addresses the most common issues found in the gut microbiota of women between the ages of 40 and 65.
 
Biohm and ADM created a formula of ingredients designed to modulate the microbiome specific to the target organisms identified in this demographic group, which includes Mycosha branded probiotic, the prebiotic PreforPro, and the postbiotic ES1. In total, seven human clinical trials and dozens of pre-clinical studies support the use of the individual ingredients in Vivifem for women’s health applications.
 
“Healthy aging and women’s health are two categories that remain ripe for opportunity, and gut microbiome balance plays a tremendous role in these areas. Our microbiome dataset allows us to create truly targeted solutions for specific groups of consumers and their needs – in this case, women over 40,” said Kristin Wilhoyte, VP of B2B marketing at Biohm Technologies. 
 
“By combining comprehensive bacterial and fungal biological data with cutting-edge computational biology and AI, we are unlocking new insights into human health. This latest formulation is a testament to this approach and there’s much more to come,” said Sam Schatz, CEO of Biohm.